Science & Enterprise subscription

Follow us on Twitter

  • Make me wanna shout ... #BillsMafia https://t.co/iF1vhKHXtu
    about 1 hour ago
  • First of two podcasts with experiences of news photographers in the insurrection. Thanks @cherissmay for sharing yo… https://t.co/aCjPD6ct84
    about 17 hours ago
  • Half or more of American adults express negative opinions about the way Covid-19 vaccines are distributed, accordin… https://t.co/9l2SUpW85u
    about 23 hours ago
  • New post on Science and Enterprise: Infographic – US Public Down on Vaccine Rollout https://t.co/vegz3ihvIO #Science #Business
    about 23 hours ago
  • We've written several times about Lander and his work, including companies he founded. ... Biden to Elevate Science… https://t.co/rWVGTa1gPL
    about 1 day ago

Please share Science & Enterprise

Illumina Adds $40M for Genomic Accelerator Start-Ups

Base sequence illustration (Genome.gov)

(Genome.gov)

26 February 2015. Illumina Inc., a developer of genomic analysis systems, is adding $40 million for investments in new enterprises based on genomic science that graduate from its accelerator program. The additional financing is provided by Viking Global Investors, an equity and hedge fund investment company in Greenwich, Connecticut.

The Illumina Accelerator program provides promising start-up companies designing products or services based on genomics with seed financing, lab space at Illumina facilities in San Francisco, access to Illumina sequencing systems, mentoring and business guidance, and non-exclusive rights to Illumina intellectual property. Seed funding consists of $100,000 in convertible notes — debt financing that converts to equity — and an unsecured credit line of $20,000. Teams in early-stage business formation are encouraged to apply, with the next application deadline set for 9 March 2015.

The new $40 million investment fund will support Illumina Accelerator participants after they emerge from the program, and will be provided as matching funds for companies raising between $1 and $5 million on their own. “This capital commitment will be instrumental in driving value for our start-ups as they advance breakthrough applications in genomics,” says Amanda Cashin, who leads Illumina Accelerator in a company statement.

The first group of three start-ups in the Illumina Accelerator was selected in October 2014:

– Biopharmaceutical company Encoded Genomics

– Agricultural therapies company EpiBiome, developing treatments for infections in dairy cattle

Xcell Biosciences, commercializing cell culture solutions for growing primary cells from a patient’s blood

The Illumina Accelerator was first formed in February 2014. Technology investor Yuri Milner provided initial seed financing, with additional funding and banking services from Silicon Valley Bank.

Read more:

*      *     *

Comments are closed.